{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.7","upperLimit":"94.7","value":"60"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75"},{"groupId":"OG002","lowerLimit":"15.8","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Timely engraftment is defined as a persistent an absolute neutrophil count (ANC) of at least 500 cells/mm3 and a platelet count of at least 20,000 cells/mm3 for at least 3 days","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells\n\nCarmustine: 300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.\n\nCytarabine: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.\n\nEtoposide: VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells\n\nMelphalan: 140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.\n\nPeripheral Blood Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"OG000","title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"OG001","title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"OG002","title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"1 month post-transplant","title":"Percentage of Participants Who Achieve a Timely Engraftment","type":"PRIMARY","unitOfMeasure":"percentage of participants who achieve a"}